Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MC4R | P32245 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070177 | 0.89 | RET (0.52) | RETHPGDRECQLCYP3A4CYP2D6 | |
| SCHEMBL20147912 | 0.87 | RET (0.50) | RETHPGDRECQLALDH1A1MEN1 | |
| SCHEMBL22857062 | 0.86 | RET (0.50) | RETHPGDRECQLCYP2D6ALDH1A1 | |
| SCHEMBL20147913 | 0.84 | RET (0.54) | RETCYP3A4CYP2D6SLC5A7MC4R | |
| SCHEMBL20158526 | 0.81 | RET (0.48) | RETCYP3A4CYP2D6SLC5A7ALDH1A1 | |
| SCHEMBL21651973 | 0.80 | RET (0.49) | RETCYP3A4CYP2D6SLC5A7ALDH1A1 | |
| SCHEMBL20147953 | 0.80 | RET (0.49) | RETALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL25502428 | 0.78 | RET (0.51) | RETCYP3A4CYP2D6SLC5A7ALDH1A1 | |
| SCHEMBL25502455 | 0.78 | RET (0.51) | RETCYP3A4CYP2D6SLC5A7ALDH1A1 | |
| SCHEMBL20069464 | 0.78 | RET (0.49) | RETCYP3A4CYP2D6SLC5A7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885HPGD 3857/4885RECQL 627/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885HPGD 3857/4885RECQL 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.